OC 10X

Drug Profile

OC 10X

Alternative Names: OC-10X

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator OcuCure Therapeutics
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy
  • Phase I Age-related macular degeneration

Most Recent Events

  • 01 Jun 2013 OcuCure Therapeutics completes a phase I trial in Healthy volunteers in Bangladesh (NCT01869933)
  • 01 Apr 2013 Phase-I clinical trials in Age-related macular degeneration (in volunteers) in Bangladesh (Ophthalmic)
  • 01 Apr 2013 Phase-I clinical trials in Diabetic retinopathy (in volunteers) in Bangladesh (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top